Ascletis Pharma Inc. (OTCMKTS:ASCLF) Sees Large Increase in Short Interest

Ascletis Pharma Inc. (OTCMKTS:ASCLF) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 185,545 shares, a growth of 576.6% from the December 15th total of 27,422 shares. Based on an average trading volume of 1,836 shares, the days-to-cover ratio is currently 101.1 days. Based on an average trading volume of 1,836 shares, the days-to-cover ratio is currently 101.1 days.

Ascletis Pharma Trading Down 1.3%

Shares of OTCMKTS ASCLF traded down $0.02 during trading on Monday, reaching $1.53. 13,000 shares of the stock were exchanged, compared to its average volume of 8,500. The business’s 50-day moving average price is $1.63 and its 200 day moving average price is $1.50. Ascletis Pharma has a twelve month low of $0.62 and a twelve month high of $2.29.

Ascletis Pharma Company Profile

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).